Daniel Kaemmerer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniel Kaemmerer has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Merten Hommann
Zentralklinik Bad Berka
3 shared publications- Richard Paul Baum
Zentralklinik Bad Berka
3 shared publications - Amelie Lupp
Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Drackendorfer Straße 1, D-07747 Jena, Germany
2 shared publications Wolfgang Daffner
Zentralklinik Bad Berka
2 shared publicationsAndreja Frilling
Imperial College London, London, United Kingdom
1 shared publicationAshley K Clift
Imperial College London, London, United Kingdom
1 shared publication
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15697
Surgery in combination with peptide receptor radionuclide therapy is effective in metastatic neuroendocrine tumors and is definable by blood gene transcript analysis.
E15697 Background: Neuroendocrine tumours (NET) of the pancreas (PNET) or small bowel (SBNET) frequently present with metastases at initial diagnosis, undermining the efficacy of surgical treatment. Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues, 90Y-DOTATOC and 177Lu-DOTATATE, has been shown to achieve prolonged progression-free survival (PFS) in a substantial number of non-surgical patients with advanced NET. Our aim was to prospectively determine the efficacy of a combination of radical loco-regional surgery and PRRT in patients with metastasised NET. Methods: A set of inclusion criteria was defined (e.g. G1/G2 NET, initial tumour diagnosis, treatment naïve patient, stage IV NET, positivity on 68Ga DOTA- PET/CT, eligibility for surgery and PRRT). Patients underwent PRRT within 3 months following surgery. Follow-up included biochemistry and imaging. In a sub-cohort, blood-based neuroendocrine gene transcript analysis of 51 genes (NETest) was used to define the effectiveness of treatment. Outcome measures included 5-year overall survival (OS) and PFS from initial diagnosis. Results: Twenty-five patients (5 PNET, 20 SBNET) met eligibility criteria and were included. There were 13 men (52%) and mean age was 57.1 years. All patients with SB NET underwent right hemicolectomy, terminal ileal resection and mesenteric lympadenectomy. In all PNET patients only limited pancreatic resection was required. The median number of PRRT cycles was 4 (range 2-6). Post-treatment mortality was 0%. Surgical morbidity was 12% (all Clavien-Dindo grade 1). Transient grade 1 toxicity occurred post-PRRT in 40%. NETest scores were increased in 8 patients (100%) pre-operatively and decreased in all following treatment. NETest decreases correlated with diminished tumour volume (R2=0.37, p=0.02). Median follow-up was 48 months (range 12-72months). Five-year OS was 90% and 5-year PFS was 84.3%. Conclusions: Radical loco-regional surgery for primary tumours combined with PRRT provides a novel, highly efficacious approach in metastasised NET. The NETest accurately measures the effectiveness of treatment.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15697
Surgery in combination with peptide receptor radionuclide therapy is effective in metastatic neuroendocrine tumors and is definable by blood gene transcript analysis.
E15697 Background: Neuroendocrine tumours (NET) of the pancreas (PNET) or small bowel (SBNET) frequently present with metastases at initial diagnosis, undermining the efficacy of surgical treatment. Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues, 90Y-DOTATOC and 177Lu-DOTATATE, has been shown to achieve prolonged progression-free survival (PFS) in a substantial number of non-surgical patients with advanced NET. Our aim was to prospectively determine the efficacy of a combination of radical loco-regional surgery and PRRT in patients with metastasised NET. Methods: A set of inclusion criteria was defined (e.g. G1/G2 NET, initial tumour diagnosis, treatment naïve patient, stage IV NET, positivity on 68Ga DOTA- PET/CT, eligibility for surgery and PRRT). Patients underwent PRRT within 3 months following surgery. Follow-up included biochemistry and imaging. In a sub-cohort, blood-based neuroendocrine gene transcript analysis of 51 genes (NETest) was used to define the effectiveness of treatment. Outcome measures included 5-year overall survival (OS) and PFS from initial diagnosis. Results: Twenty-five patients (5 PNET, 20 SBNET) met eligibility criteria and were included. There were 13 men (52%) and mean age was 57.1 years. All patients with SB NET underwent right hemicolectomy, terminal ileal resection and mesenteric lympadenectomy. In all PNET patients only limited pancreatic resection was required. The median number of PRRT cycles was 4 (range 2-6). Post-treatment mortality was 0%. Surgical morbidity was 12% (all Clavien-Dindo grade 1). Transient grade 1 toxicity occurred post-PRRT in 40%. NETest scores were increased in 8 patients (100%) pre-operatively and decreased in all following treatment. NETest decreases correlated with diminished tumour volume (R2=0.37, p=0.02). Median follow-up was 48 months (range 12-72months). Five-year OS was 90% and 5-year PFS was 84.3%. Conclusions: Radical loco-regional surgery for primary tumours combined with PRRT provides a novel, highly efficacious approach in metastasised NET. The NETest accurately measures the effectiveness of treatment.
- 29 November 2016
- Published by Bioscientifica in Endocrine Abstracts
Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large series of paragangliomas
Background: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed. Aims: In the present study the expression of the five somatostatin receptor (SSTR) subtypes as well as of the chemokine receptor CXCR4 and of the endothelin receptor A (ETA) was evaluated. Methods: Receptor expression was assessed by means of immunohistochemistry using a panel of novel rabbit monoclonal antibodies in a total of 54 paraffin-embedded paraganglioma tumor samples from 43 patients. The stainings were rated by means of the Immunoreactive Score and correlated to clinical data. Results: The SSTR2 was by far the most prominent receptor in the paragangliomas investigated. It was present in all samples at a high intensity, followed by the SSTR5, the SSTR1, the SSTR3 and the SSTR4. The CXCR4 and the ETA were seen only in a few cases on the tumor cells. However, with respect to the tumor blood vessels, in all cases an exceptionally strong staining for the ETA and in the majority of the samples also for the CXCR4 was noticed. Conclusions: Due to the high expression rate found in the present study, paragangliomas seem to be well suited for SSTR2-based diagnostics and therapies. Additionally, an indirect targeting of these highly vascularized tumors via the CXCR4 or the ETA may represent a promising future strategy.
- 29 November 2016
- Published by Bioscientifica in Endocrine Abstracts
Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large series of paragangliomas
Background: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed. Aims: In the present study the expression of the five somatostatin receptor (SSTR) subtypes as well as of the chemokine receptor CXCR4 and of the endothelin receptor A (ETA) was evaluated. Methods: Receptor expression was assessed by means of immunohistochemistry using a panel of novel rabbit monoclonal antibodies in a total of 54 paraffin-embedded paraganglioma tumor samples from 43 patients. The stainings were rated by means of the Immunoreactive Score and correlated to clinical data. Results: The SSTR2 was by far the most prominent receptor in the paragangliomas investigated. It was present in all samples at a high intensity, followed by the SSTR5, the SSTR1, the SSTR3 and the SSTR4. The CXCR4 and the ETA were seen only in a few cases on the tumor cells. However, with respect to the tumor blood vessels, in all cases an exceptionally strong staining for the ETA and in the majority of the samples also for the CXCR4 was noticed. Conclusions: Due to the high expression rate found in the present study, paragangliomas seem to be well suited for SSTR2-based diagnostics and therapies. Additionally, an indirect targeting of these highly vascularized tumors via the CXCR4 or the ETA may represent a promising future strategy.
- 1 February 2016
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 41 (2) , e111-e114
Localization of Radiolabeled Somatostatin Analogs in the Spleen
Radiolabeled somatostatin (SST) analogs, used to visualize and treat SST receptor (SSTR)-expressing neuroendocrine tumors, also accumulate in the spleen. There is a high interpatient variation and no significant radiation-induced splenic toxicity; however, an absorbed dose-related reduction in spleen size was detected. However, the exact localization of radioactivity and the role of SST receptors in splenic retention are unknown. Therefore, we performed ex vivo micro-SPECT of the isolated spleen from a patient with a pancreatic neoplasm after 1 GBq (27 mCi) Lu-DOTATATE administration, followed by autoradiography and immunohistochemistry. Ex vivo autoradiography demonstrated convincingly that most radioactivity accumulated in red pulp.
- 1 February 2016
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 41 (2) , e111-e114
Localization of Radiolabeled Somatostatin Analogs in the Spleen
Radiolabeled somatostatin (SST) analogs, used to visualize and treat SST receptor (SSTR)-expressing neuroendocrine tumors, also accumulate in the spleen. There is a high interpatient variation and no significant radiation-induced splenic toxicity; however, an absorbed dose-related reduction in spleen size was detected. However, the exact localization of radioactivity and the role of SST receptors in splenic retention are unknown. Therefore, we performed ex vivo micro-SPECT of the isolated spleen from a patient with a pancreatic neoplasm after 1 GBq (27 mCi) Lu-DOTATATE administration, followed by autoradiography and immunohistochemistry. Ex vivo autoradiography demonstrated convincingly that most radioactivity accumulated in red pulp.
- 12 November 2010
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 25 (2) , 177
Strange sensation after a chicken stew
- 12 November 2010
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 25 (2) , 177
Strange sensation after a chicken stew
- 4 June 2010
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 396 (2) , 261-265
Reconstruction of a total avulsion of the hepatic veins and the suprahepatic inferior vena cava secondary to blunt thoracoabdominal trauma
- 4 June 2010
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 396 (2) , 261-265
Reconstruction of a total avulsion of the hepatic veins and the suprahepatic inferior vena cava secondary to blunt thoracoabdominal trauma
- Open Access
- 15 February 2010
- Published by Frontiers Media SA in Transplant International
- Vol. 23 (7) , 753-759
Treatment of osteoporosis after liver transplantation with ibandronate
Osteoporosis is a major side‐effect after liver transplantation (LTX). Therefore, the objective of the study was to evaluate the efficacy of ibandronate to reduce fractures after LTX. Seventy‐four patients after LTX were included in the study and measurements of bone mineral density (BMD) of lumbar spine and proximal femur using dual energy X‐ray absorptiometry (DEXA) were performed prior to and 3, 6, 12 and 24 months after surgery. The study group (IBA) consisted of 34 patients who received calcium (1 g/day), vitamin D3 (800–1000 IE/day) and ibandronate 2 mg every 3 months intravenously for 1 year. The control group consisted of 40 patients (CON) who received calcium and vitamin D3 at the same dosages. Prevalence of new fractures was predefined as primary endpoint. Changes of BMD and biochemical markers of bone metabolism were also investigated. In all patients, we found a reduction of BMD in the first few months after LTX. In the lumbar spine and the proximal femur the maximum reduction occurred 3 and 6 months post‐LTX. One and 2 years after transplantation, the group receiving ibandronate demonstrated a better recovery from loss of BMD and a significantly lower prevalence of fractures (IBA 2 vs. CON 10 P < 0.04, χ2). Ibandronate with calcium and vitamin D3 reduces the BMD‐loss after LTX and decreases the rate of bone fractures significantly.
- 15 February 2010
- Published by Frontiers Media SA in Transplant International
- Vol. 23 (7) , 753-759
Open AccessTreatment of osteoporosis after liver transplantation with ibandronate
Osteoporosis is a major side‐effect after liver transplantation (LTX). Therefore, the objective of the study was to evaluate the efficacy of ibandronate to reduce fractures after LTX. Seventy‐four patients after LTX were included in the study and measurements of bone mineral density (BMD) of lumbar spine and proximal femur using dual energy X‐ray absorptiometry (DEXA) were performed prior to and 3, 6, 12 and 24 months after surgery. The study group (IBA) consisted of 34 patients who received calcium (1 g/day), vitamin D3 (800–1000 IE/day) and ibandronate 2 mg every 3 months intravenously for 1 year. The control group consisted of 40 patients (CON) who received calcium and vitamin D3 at the same dosages. Prevalence of new fractures was predefined as primary endpoint. Changes of BMD and biochemical markers of bone metabolism were also investigated. In all patients, we found a reduction of BMD in the first few months after LTX. In the lumbar spine and the proximal femur the maximum reduction occurred 3 and 6 months post‐LTX. One and 2 years after transplantation, the group receiving ibandronate demonstrated a better recovery from loss of BMD and a significantly lower prevalence of fractures (IBA 2 vs. CON 10 P < 0.04, χ2). Ibandronate with calcium and vitamin D3 reduces the BMD‐loss after LTX and decreases the rate of bone fractures significantly.
- Open Access
- 1 January 2009
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 15 (46) , 5867-5870
Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
- 1 January 2009
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 15 (46) , 5867-5870
Open AccessNeoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor